natgillin/translations-raw huggingface dataset:
A non-human expression system comprising the nucleotide sequence according to claim 16. 
Ne-humani ekspresijski sustav naznačen time da sadrži nukleotidnu sekvencu prema zahtjevu 16.
A non-human transgenic animal expressing a nucleotide sequence encoding an amyloid precursor protein (APP) according to claim 14 or 15. 
Ne-humana transgena životinja koja eksprimira nukleotidnu sekvencu koja kodira amiloidni prekursorski protein (APP) prema zahtjevu 14 ili 15.
The non-human transgenic animal according to claim 18, wherein said APP is a mutated human APP, preferably wherein said APP is the protein SEQ ID NO: 11. 
Ne-humana transgena životinja prema zahtjevu18, naznačena time da navedeni APP je mutirani ljudski APP, poželjno pri čemu je navedeni APP protein iz SEQ ID NO: 11.
each RP is independently a ring substituent; 
Svaki RP je neovisno supstitent u prstenu;
and wherein additionally, two ring adjacent ring substituents may together form a group -O-L1-O-, wherein L1 is independently saturated aliphatic C1-3alkylene; and wherein: 
[image] i pritom dodatno, dva susjedna supstituenta u prstenu, mogu zajedno tvoriti skupinu -O-L1-O-, gdje L1 je neovisno zasićeni alifatski C1-3-alkilen; i pri čemu:
in each group -NRN1RN2, RN1 and RN2, taken together with the nitrogen atom to which they are attached, form a 5-, 6-, or 7-membered non-aromatic ring having exactly 1 ring heteroatom or exactly 2 ring heteroatoms, wherein one of said exactly 2 ring heteroatoms is N, and the other of said exactly 2 ring heteratoms is independently N or O; 
u svakoj skupini -NRN1RN2, Rn1 i RN2 kada se uzmu zajedno s dušikovim atomom na kojega su priključeni, tvore 5-člani, 6-člani ili 7-člani nearomatski prsten koji ima točno jedan heteroatom u prstenu ili točno dva heteroatoma u prstenu, gdje jedan od navedena točno dva heteroatoma u prstenuje N, a preostali od navedena točno dva heteroatoma u prstenu, neovisno je N ili O;
each -RF1 is independently saturated aliphatic C1-4alkyl; each -L3- is independently saturated aliphatic C2-5alkylene; and in each group -NRN3RN4, RN3 and RN4, taken together with the nitrogen atom to which they are attached, form a 5-, 6-, or 7-membered non-aromatic ring having exactly 1 ring heteroatom or exactly 2 ring heteroatoms, wherein one of said exactly 2 ring heteroatoms is N, and the other of said exactly 2 ring heteratoms is independently N or O. 
svaki -Rfi je neovisno zasićeni alifatski C1-4-alkil; svaki -L - je neovisno zasićeni alifatski C2-5-alkilen; i u svakoj skupini -NRN3RN4, RN3 i RN4 kada se uzmu zajedno s dušikovim atomom na kojega su priključeni, tvore 5-člani, 6-člani ili 7-člani nearomatski prsten koji ima točno jedan heteroatom u prstenu ili točno dva heteroatoma u prstenu, gdje jedan od navedena točno dva heteroatoma u prstenuje N, a preostali od navedena točno dva heteroatoma u prstenu, neovisno je N ili O.
wherein each RP is independently a ring substituent; or wherein Ar1-Ar2- is independently a group of the following formula: 
[image] gdje Rp je neovisno supstituent u prstenu; ili gdje Ar1-Ar2- je neovisno skupina sljedeće formule:
A pharmaceutical composition comprising a compound according to any one of claims 1 to 13 and a pharmaceutically acceptable carrier or diluent. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 13 i farmaceutski prikladan nosač ili razrjeđivač.
A pharmaceutical composition for oral administration comprising a compound according to any one of claims 1 to 13 and a pharmaceutically acceptable carrier or diluent. 
Farmaceutski sastav za oralnu primjenu, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 13 i farmaceutski prikladan nosač ili razrjeđivač.
a disorder associated with inflammation or activation of the immune system; 
poremećaj povezan s upalom ili s aktiviranjem imunološkog sustava;
an immune response leading to organ or graft rejection following transplant; a tumor which over expresses TNFa, IL-1, or RANKL or in which inhibition of TNFa, IL-1, or RANKL facilitates or improves the action of cytotoxic tumoricidal agents; 
imunološka reakcija koja vodi do odbacivanja organa ili presadaka nakon transplantacije; tumor koji prekomjerno izražava TNFa, IL-1 ili RANKL, ili kod kojega inhibicija za TNFa, IL-1 ili za RANKL, olakšava ili poboljšava djelovanje citotoksičnih tumoricidnih sredstava;
a disorder characterised by excessive bone resorption; 
poremećaj karakteriziran prekomjernom resorpcijom kostiju;
bone loss associated with excessive osteoclast activation; 
gubitak kostiju povezan s prekomjernim aktiviranjem osteoklasta;
joint destruction associated with inflammation; 
razaranje zglobova povezano s upalom;
joint destruction associated with excessive osteoclast activation; 
razaranje zglobova povezano s prekomjernim aktiviranjem osteoklasta;
psoriatic arthritis; ankylosing spondylitis; inflammatory bowel disease; 
psorijatički artritis; ankilozni spondilitis; upalna bolest crijeva;
an immune response leading to organ or graft rejection following transplant; 
imunološka reakcija koja vodi do odbacivanja organa ili presadaka nakon transplantacije;
a tumor which over expresses TNFa, IL-1, or RANKL or in which inhibition of TNFa, IL-1, or RANKL facilitates or improves the action of cytotoxic tumoricidal agents; 
tumor koji prekomjerno izražava TNFa, IL-1 ili RANKL, ili kod kojega inhibicija za TNFa, IL-l ili za RANKL, olakšava ili poboljšava djelovanje citotoksičnih tumoricidnih sredstava;
A compound according to claim 1 selected from: 
Spoj prema zahtjevu 1 naznačen time da je odabran iz skupa koji sadrži:
or an enantiomer, diastereomer, solvate, or pharmaceutically acceptable salt thereof. 
ili enantiomer, diastereomer, solvat, ili njihova farmaceutski prihvatljiva sol.
A compound of any one of claims 1 to 18, or an enantiomer, diastereomer, solvate, or pharmaceutically acceptable salt thereof for use in treating a disease modulated by a metalloprotease in a mammalian subject, wherein the disease is selected from arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions. 
Spoj prema bilo kojem od zahtjeva 1 do 18, ili enantiomer, diastereomer, solvat, ili njihova farmaceutski prihvatljiva sol naznačen time da je za uporabu za liječenje bolesti modulirane s metaloproteazom kod subjekta koji je sisavac, pri čemu je bolest odabrana od artritisa, raka, kardiovaskularnih poremećaja, kožnih poremećaja, upale i alergijskih stanja.
A compound of any one of claims 1 to 18, or an enantiomer, diastereomer, solvate, or pharmaceutically acceptable salt thereof for use in treating a disease associated with unwanted matrix metalloprotease activity wherein said matrix metalloprotease is selected from the group consisting of MMP12, MMP14, MMP3, MMP2, and MMP9 in a mammalian subject. 
Spoj prema bilo kojem od zahtjeva 1 do 18, ili enantiomer, diastereomer, solvat, ili njihova farmaceutski prihvatljiva sol naznačen time da je za uporabu za liječenje bolesti povezane s neželjenom aktivnošću matrične metaloproteaze pri čemu je navedena matrična metaloproteaza odabrana iz skupine koja sadrži MMP12, MMP14, MMP3, MMP2, i MMP9 kod subjekta koji je sisavac.
A compound of any one of claims 1 to 18, or an enantiomer, diastereomer, solvate, or pharmaceutically acceptable salt thereof for use in treating a disease associated with unwanted ADAM10, ADAM 15, or ADAM 17 activity in a mammalian subject. 
Spoj prema bilo kojem od zahtjeva 1 do 18, ili enantiomer, diastereomer, solvat, ili njihova farmaceutski prihvatljiva sol naznačen time da je za uporabu za liječenje bolesti povezane s neželjenom aktivnošću ADAM10, ADAM 15, ili ADAM 17 kod subjekta koji je sisavac.
binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and 
da se sprečava vezanje IGF-1 i IGF-2 na receptor IGF-1 i
does not bind to human insulin; 
ne veže na ljudski inzulin;
The antibody molecule of claim 1, which has a variable heavy chain comprising the amino acid sequence of SEQ ID NO:28. 
Molekula protutijela prema zahtjevu 1, naznačena time, da ima varijabilni jaki lanac koji obuhvaća aminokiselinsku sekvencu SEQ ID NO:28.
The antibody molecule of claim 1, which has a variable light chain comprising the amino acid sequence of SEQ ID NO:30. 
Molekula protutijela prema zahtjevu 1, naznačena time, da ima varijabilni slabi lanac koji obuhvaća aminokiselinsku sekvencu SEQ ID NO:30.
The antibody molecule of any one of claims 1 to 3, comprising a heavy chain constant region selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgE constant regions. 
Molekula protutijela prema bilo kojem od zahtjeva 1 do 3, naznačena time, da obuhvaća konstantno područje jakog lanca odabrano iz skupine koju čine sljedeća konstantna područja: IgG1, IgG2, IgG3, IgG4, IgM, IgA i IgE.
a heavy chain comprising the amino acid sequence of SEQ ID NO:39, and 
jaki lanac koji obuhvaća aminokiselinsku sekvencu SEQ ID NO:39, i
a light chain comprising the amino acid sequence of SEQ ID NO:40. 
slabi lanac koji obuhvaća aminokiselinsku sekvencu SEQ ID NO:40.
A DNA molecule encoding the variable heavy chain and the variable light chain of an antibody molecule of any one of claims 1 to 9. 
Molekula DNK, naznačena time, da kodira varijabilni jaki lanac i varijabilni slabi lanac od molekule protutijela prema bilo kojem od zahtjeva 1 do 9.
The DNA molecule of claim 10 which has the nucleotide sequence of SEQ ID NO: 27, encoding the variable heavy chain of the antibody defined in claim 2, and which has the nucleotide sequence of SEQ ID NO: 29, encoding the variable light chain of the antibody defined in claim 3. 
Molekula DNK prema zahtjevu 10, naznačena time, da ima nukleotidnu sekvencu SEQ ID NO:27 koja kodira varijabilni jaki lanac od protutijela prema zahtjevu 2, te time, da ima nukleotidnu sekvencu SEQ ID NO:29 koja kodira varijabilni slabi lanac od protutijela prema zahtjevu 3.
An expression vector containing a DNA molecule comprising the nucleotide sequence encoding the variable heavy chain and the variable light chain of an antibody molecule of any one of claims 1 to 9. 
Vektor ekspresije, naznačen time, da sadrži molekulu DNK koja obuhvaća nukleotidnu sekvencu koja kodira varijabilni jaki lanac i varijabilni slabi lanac od molekule protutijela prema bilo kojem od zahtjeva 1 do 9.
The antibody molecule of claim 21, wherein the medicament is to be used in combination with platinum-based chemotherapy, in particular paclitaxel/carboplatin or gemcitabine/cisplatin platinum doublet therapy, sorafenib, or a compound selected from the group of inhibitors of EGFR, VEGF, HER2-neu, AuroraB, Plk1, PI3 kinase, or mTor. 
Molekula protutijela prema zahtjevu 21, naznačena time, da se lijek upotrebljava u kombinaciji s kemoterapijom na platinskoj bazi, posebno s platinskom duplikatnom terapijom paklitaksel/karboplatin ili gemcitabin/cisplatin, sorafenib ili sa spojem odabranim iz skupine inhibitora za EGFR, VEGF, HER2-neu, AuroraB, Plk1, -kinazu ili mTor.
A pharmaceutical composition comprising an antibody molecule of any one of claims 1 to 9 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća molekulu protutijela prema bilo kojem od zahtjeva 1 do 9 i farmaceutski prikladan nosač.
therapeutically active compounds that inhibit signal transduction pathways or mitotic checkpoints in cancer cells, 
terapeutski djelotvorni spojevi koji inhibiraju puteve prijenosa signala ili mitotske kontrolne točke u stanicama raka,
An in-vitro method for monitoring the effectiveness of a treatment of a cancer patient with an antibody molecule that binds to IGF-1 and IGF-2, wherein said antibody molecule is an antibody molecule of any one of claims 1 to 9, wherein said method comprises 
In vitro postupak kontrole učinkovitosti liječenja pacijenta od raka s molekulom protutijela koja se veže na IGF-1 i IGF-2, pri čemu navedena molekula protutijela je molekula protutijela prema bilo kojem od zahtjeva 1 do 9, naznačen time, da navedeni postupak obuhvaća sljedeće:
compound of formula (XX) is prepared in step (M1); 
da spoj formule (XX) bude spravljen u koraku (M1);
reagent (M-A) is selected from the group consisting of ammonia, sulfamic acid, p-toluenesulfonamide, benzenesulfonamide, 4-acetamidobenzenesulfonamide, tritylamine, formamide, urea, urotropine, ethyl carbamate, acetamide and mixtures thereof; solvent (M-solv) is selected from the group consisting of N,N-dimethylformamide, C1-6 alkanol, formamide, 1,2-dimethoxyethane, NMP, toluene, acetonitrile, propionitrile, ethyl carbamate, N,N-dimethylacetamide, water, acetamide and mixtures thereof; 
reagens (M-A) će biti odabran iz skupine koja se sastoji iz amonijaka, sulfamidne kiseline, p-toluolsulfonamida, benzolsulfonamida, 4-acetamidobenzolsulfonamida, tritilamina, formamida, uree, urotropina, etilnog estera karbamidne kiseline, acetamida i njihovih mješavina; otapalo (M-otap.) će biti odabrano iz skupine koja se sastoji iz N,N-dimetilformamida, C1-6 alkanola, formamida, 1,2-dimetoksietana, NMP, toluola, acetonitrila, propionitrila, etilnog estera karbamidne kiseline, N,N-dimetilacetamida, vode, acetamida i njihovih mješavina;
compound of formula (XXI) is prepared in step (N); 
spoj formule (XXI) će biti spravljen u koraku (N);
reagent (Q1-reag) is selected from the group consisting of lithium, magnesium, aluminum, zinc, calcium, propylmagnesium chloride, propylmagnesium bromide, butyllithium and mixtures thereof; 
reagens (Q1-reag.) će biti odabran iz skupine koja se sastoji iz litija, magnezija, aluminija, cinka, kalcija, propilmagnezijklorida, propilmagnezijbromida, butillitija i njihovih mješavina;
reaction (Q2-reac) is a reaction of the reaction product of reaction (Q1-reac) with chloroacetone; 
kod reakcije (Q2-reak.) se radi o reakciji reakcijskog produkta reakcije (Q1-reak.) s kloracetonom;
compound of formula (XXII) is prepared by the reaction (Q2-reac). 
spoj formule (XXII) će biti spravljen kroz reakciju (Q2-reak.).
Method according to claim 1, wherein step (M1) comprises two consecutive steps, a first step (M1-A1-1) and a second step (M1-A1-2); 
Postupak prema zahtjevu 1, naznačen time da korak (M1) obuhvaća dva nastavno odvojena koraka, prvi korak (M1-A1-1) i drugi korak (M1-A1-2);
reaction (M1-A1-2) is a reaction of the reaction product of reaction (M1-A1-1) with reagent (M-A) in solvent (M-solv). 
kod reakcije (M1-A1-2) se radi o reakciji reakcijskog produkta reakcije (M1-A1-1) s reagensom (M-A) u otapalu (M-otap.).
Method according to claim 1 or 2, wherein reagent (M-reag) is selected from the group consisting of p-toluenesulfonylmethyl isocyanide, benzenesulfonylmethyl isocyanide and mixtures thereof. 
Postupak prema zahtjevu 1 ili 2, naznačen time da će reagens (M-reag.) biti odabran iz skupine koja se sastoji iz p-toluolsulfonilmetilizocijanida, benzolsulfonilmetilizocijanida i njihovih mješavina.
Method according to one or more of claims 1 to 3, wherein reagent (M-A) is selected from the group consisting of ammonia, sulfamic acid, p-toluenesulfonamide, benzenesulfonamide, 4-acetamidobenzenesulfonamide, tritylamine, formamide and mixtures thereof. 
Postupak prema jednom ili više zahtjeva 1 do 3, naznačen time da će reagens (M-A) biti odabran iz skupine koja se sastoji iz amonijaka, sulfamidne kiseline, p-toluolsulfonamida, benzolsulfonamida, acetamidobenzolsulfonamida, tritilamina, formamida i njihovih mješavina.
Method according to one or more of claims 1 to 4, wherein solvent (M-solv) is selected from the group consisting of N,N-dimethylformamide, methanol, ethanol, n-propanol, isopropanol, butanol, pentanol, hexanol, water, formamide, 1,2-dimethoxyethane, NMP, toluene, acetonitrile, propionitrile, ethyl carbamate, N,N-dimethylacetamide, acetamide and mixtures thereof. 
Postupak prema jednom ili više zahtjeva 1 do 4, naznačen time da će otapalo (M-otap.) biti odabrano iz skupine koja se sastoji iz N,N-dimetilformamida, metanola, etanola, n-propanola, izopropanola, butanola, pentanola, heksanola, vode, formamida, 1,2-dimetoksietana, NMP, toluola, acetonitrila, propionitrila, etil estera karbamidne kiseline, N,N-dimetilacetamida, acetamida i njihovih mješavina.
Method according to claim 6, wherein compound (M-comp) is selected from the group consisting of ammonia, tritylamine, NaCN, KCN, piperidine, tBuOK, tBuONa, KOH, K2CO3, Na2CO3, KF and mixtures thereof. 
Postupak prema zahtjevu 6, naznačen time da će spoj (M-spoj) biti odabran iz skupine koja se sastoji iz amonijaka, tritilamina, NaCN, KCN, piperidina, tBuOK, tBuONa, KOH, K2CO3, Na2CO3, KF i njihovih mješavina.
Method according to one or more of claims 1 to 7, wherein catalyst (N-cat) is selected from the group consisting of acetic acid, formic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, HCl, HBr, H2SO4, H3PO4, BCl3, BF3OEt2, MgCl2, MgBr2, AlCl3, ZnCl2, Cu(BF4)2, aluminosilicate, acidic ion exchange resin, carbon treated with HCl, H2SO4 or HNO3,and mixtures thereof. 
Postupak prema jednom ili više zahtjeva 1 do 7, naznačen time da će katalizator (N-kat.) biti odabran iz skupine koja se sastoji iz octene kiseline, mravlje kiseline, trifluoroctene kiseline, metansulfonske kiseline, p-toluolsulfonske kiseline, HCl, HBr, H2SO4, H3PO4, BCl3, BF3OEt2, MgCl2, MgBr2, AlCl3, ZnCl2, Cu(BF4)2, aluminosilikata, kiselih smola ionskih izmjenjivača, ugljika tretiranog s HCl, H2SO4 ili HNO3 i njihovih mješavina.
Method according to one or more of claims 1 or 9, wherein reagent (Q1-reag) is selected from the group consisting of lithium, magnesium, aluminum, isopropylmagnesium chloride, isopropylmagnesium bromide, n-butyllithium, sec-butyllithium, tert-butyllithium, and mixtures thereof. 
Postupak prema jednom ili više zahtjeva 1 do 9, naznačen time da će reagens (Q1-reag.) biti odabran iz skupine koja se sastoji iz litija, magnezija, aluminija, izopropilmagnezij klorida, izopropilmagnezij bromida, n-butillitija, sek.-butillitija, terc.-butillitija i njihovih mješavina.
Method according to one or more of claims 1 to 10, wherein reaction (Q1-reac) is done in the presence of a catalyst (Q1-cat); 
Postupak prema jednom ili više zahtjeva 1 do 10, naznačen time da će reakcija (Q1-reak.) biti provedena u nazočnosti katalizatora (Q1-kat.);
catalyst (Q1-cat) is selected from the group consisting of iodine, 1,2-dibromoethane, TiCl4, AlCl3, PbCl2, BiCl3, LiCl and mixtures thereof. 
katalizator (Q1-kat.) će biti odabran iz skupine koja se sastoji iz joda, 1,2-dibrometana, TiCl4, AlCl3, PbCl2, BiCl3, LiCl i njihovih mješavina.
increasing a temperature of the amorphous frozen product to produce a crystalline frozen product; 
povećavanja temperature amorfnog zamrznutog produkta kako bi se proizveo kristalni zamrznuti produkt;
cooling the crystalline frozen product again; and 
ponovnog hlađenja kristalnog zamrznutog produkta; i
the first sweetener being selected from the group consisting of cyclamate and a cyclamate salt; the second sweetener being selected from the group consisting of saccharine and a saccharine salt; the third sweetener being selected from the group consisting of acesulfame and an acesulfame salt; 
prvo sladilo odabrano je iz skupine koja se sastoji od ciklamata i soli ciklamata; drugo sladilo odabrano je iz skupine koja se sastoji od saharina i soli saharina; treće sladilo odabrano je iz skupine koja se sastoji od acesulfama i soli acesulfama;
The composition according to any of the preceding claims, wherein the mixture of sweeteners consists of the first, of the second and of the third sweetener. 
Sastavina sukladno bilo kojem od prethodnih zahtjeva, pri čemu se mješavina sladila sastoji od prvog, drugog i trećeg sladila.
A tablet or capsule comprising a pharmaceutical composition, wherein the pharmaceutical composition comprises apixaban and a pharmaceutically acceptable diluent or carrier, wherein the apixaban is in particulate and crystalline form and the individual apixaban particles, whether the particles exist singly or are agglomerated, have a D90 equal to or less than 89 µm as measured by laser light scattering. 
Tableta ili kapsula koja sadrži farmaceutsku kompoziciju, gdje farmaceutska kompozicija sadrži apiksaban i farmaceutski prihvatljiv razrijeđivač ili nosač, gdje je apiksaban u obliku tvari i kristalnom obliku i pojedinačne tvari apiksabana, bilo da tvari postoje zasebno ili u aglomeratu, imaju D90 jednak ili manji od 89 µm kao što je mjereno raspršivanjem laserske svjetlosti.
The tablet or capsule as defined in claim 7, wherein the surfactant is sodium lauryl sulfate. 
Tableta ili kapsula kao što je određena u patentnom zahtjevu 7, gdje je surfaktant natrijev lauril sulfat.
blending raw materials prior to granulation; 
miješanje sirovih materijala prije granulacije;
blending the granules obtained in the step (2) with extragranular raw materials; 
miješanje granula dobijenih u koraku (2) sa ekstragranuloznim sirovim materijalom;
compressing the blend from the step (3) into a tablet; and 
komprimiranje smjese iz koraka (3) u tabletu; i
film coating the tablet from the step (4). 
oblaganje filmom tablete iz koraka (4).
granulating the materials from the step (2) using a dry granulation process or a wet granulation process, wherein the dry granulation process comprises: 
granuliranje materijala iz koraka (2) korištenjem postupka suhe granulacije ili postupka vlažne granulacije, gdje postupak suhe granulacije obuhvaća:
compacting the lubricated blend to ribbons of density in a range of 1.1 to 1.2 g/cc and sizing the compacted ribbons using a roller compactor, and wherein the wet granulation process comprises: 
sabijanje ovlažene smjese u trake gustoće u opsegu od 1.1 do 1.2 g/cc i formiranje do dobijene veličine sabijenih traka uporabom valjka kompaktora, i gdje postupak vlažne granulacije obuhvaća:
blending the granules obtained in the step (3) and an extragranular disintegrant in a blender; 
miješanje granula dobijene veličine iz koraka (3) i ekstragranuloznog sredstva za raspadanje u miješalici;
delumping an extragranular lubricant using a screen or mill and blending with granules from the step (4); 
uklanjanje grudica iz ekstragranularnog lubrikanta uporabom sita ili mlina i miješanje sa granulama iz koraka (4);
compressing the blend from the step (5) into a tablet; and 
komprimiranje smjese iz (5) u tablete; i
An isolated immunogenic polypeptide comprising a variant Protein A (SpA) D domain having (a) at least two amino acid substitutions that disrupt Fc binding comprising an amino acid substitution at each of the amino acid positions corresponding to amino acid positions 9 and 10 of SEQ ID NO:2 and (b) at least two amino acid substitutions that disrupt VH3 binding comprising an amino acid substitution at each of the amino acid positions corresponding to amino acid positions 36 and 37 of SEQ ID NO:2 and (c) an amino acid sequence that is at least 70% identical to the amino acid sequence of SEQ ID NO:2. 
Izolirani imunogenički polipeptid koji sadrži varijantu D domene proteina A (SpA) koja ima (a) najmanje dvije supstitucije aminokiseline koje ometaju Fc vezanje koje sadrže supstituciju aminokiseline na svakom položaju aminokiseline koji odgovara položajima aminokiselina 9 i 10 sa SEQ ID NO:2 i (b) najmanje dvije supstitucije aminokiseline koje ometaju VH3 vezanje koje sadrže supstituciju aminokiseline na svakom položaju aminokiseline što odgovara položajima aminokiselina 36 i 37 sa SEQ ID NO:2 i (c) sekvencu aminokiseline koje je najmanje 70 % identična sekvenci aminokiseline sa SEQ ID NO:2.
The polypeptide of claim 1, wherein for (a) the amino acid substitution is a lysine residue for a glutamine residue. 
Polipeptid prema zahtjevu 1, naznačen time, što je (a) supstitucija aminokiseline ostatak lizina koji supstituira ostatak glutamina.
The polypeptide of claim 1, wherein for (a) the amino acid substitution is a glycine residue for a glutamine residue. 
Polipeptid prema zahtjevu 1, naznačen time, što je (a) supstitucija aminokiseline ostatak glicina koji supstituira ostatak glutamina.
one or more variants of an SpA E domain, A domain, B domain, or C domain; 
jednu ili više varijanti SpA E domene, A domene, B domene ili C domene;